| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/22/2009 | EP1507529B1 Combination comprising valsartan, amlodipine and hydrochlorothiazide |
| 04/22/2009 | EP1505974B1 Use of compounds that are effective as selective opiate receptor modulators |
| 04/22/2009 | EP1480630B1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa |
| 04/22/2009 | EP1381366B1 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 04/22/2009 | EP1379873B1 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 04/22/2009 | EP1368004B1 Mucoadhesive dispersible pharmaceutical preparation for active-agent dosing in veterinary and human medicine |
| 04/22/2009 | EP1364069B1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes |
| 04/22/2009 | EP1317419B1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 04/22/2009 | EP1207809B1 Metering and packaging of controlled release medication |
| 04/22/2009 | EP1049459B1 Oral liquid compositions |
| 04/22/2009 | EP0959897B1 Method of regulating nitric oxide production |
| 04/22/2009 | CN101415443A Compositions of stabilized DNA for coating microprojctions |
| 04/22/2009 | CN101415441A Healing composition |
| 04/22/2009 | CN101415440A Method for treating lung cancer |
| 04/22/2009 | CN101415424A Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| 04/22/2009 | CN101415422A Anti-cancer pharmaceutical composition |
| 04/22/2009 | CN101412758A Anti-ErbB2 antibodies |
| 04/22/2009 | CN100480387C GBS toxin receptor |
| 04/22/2009 | CN100480275C Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing the complexes |
| 04/22/2009 | CN100479862C Transporters and drug delivery system by using the same |
| 04/22/2009 | CN100479860C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 04/22/2009 | CN100479857C Anti-HIV medicine |
| 04/22/2009 | CN100479856C Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 04/22/2009 | CN100479824C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 04/22/2009 | CN100479814C Use of accelerated lymphocyte homing agents for manufacture of medicament for treating delayed graft function in tissue transplant |
| 04/22/2009 | CN100479808C Fibrate tablet and production method thereof |
| 04/21/2009 | US7521479 Administering chaotropic agent |
| 04/21/2009 | US7521455 Histamine H3 receptor antagonist or inverse agonist activity; metabolic diseases, circulatory diseases, or nervous system diseases; e.g. 3-(4-((1-cyclobutyl-4-piperidinyl)oxy)phenyl)-2-ethylpyrido(2,3-d)pyrimidin-4(3H)-one |
| 04/21/2009 | US7521450 Inhibitors of kinases |
| 04/21/2009 | US7521445 Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands |
| 04/21/2009 | US7521438 Allergies,chronic obstructive airway disorders (COPD), e.g. bronchial asthma, chronic obstructive bronchitis, pulmonary emphysema with reversible obstruction, bronchial asthma and other bronchial disorders; side effect reduction |
| 04/21/2009 | US7521423 Exendin pharmaceutical compositions |
| 04/21/2009 | US7521418 When used in combination with glycopeptide antibacterial agent, the amount of polyene macrolide antifungal agent needed to treat a fungal infection is reduced thereby resulting in fewer side effects |
| 04/21/2009 | US7521414 Polyene-polyol structure; anticancer agents |
| 04/21/2009 | US7521229 replication-defective recombinant adenovirus comprising a heterologous nucleic acid sequence encoding an antigenic determinant of Plasmodium falciparum; ntigenic determinant comprises an immunogenic peptide of the circumsporozoite protein; viral vectors |
| 04/21/2009 | US7521215 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents |
| 04/21/2009 | US7521206 Tumor necrosis factor (TNF); immunotherapy or diagnosis of TNF-related diseases such as cancer; nucleic acids, host cells, vectors |
| 04/21/2009 | US7521068 For pulmonary and nasal drug administration |
| 04/21/2009 | US7521064 Insertion into vagina; prevention, therapy for infections |
| 04/21/2009 | US7521063 A polynucleotides comprise an unmethylated CpG motif, as stimulates and enhancing the efficacy of a vaccine |
| 04/21/2009 | US7521062 Thiosemicarbazones as anti-virals and immunopotentiators |
| 04/21/2009 | US7521053 Angiopoietin-2 specific binding agents |
| 04/21/2009 | US7521040 Immunotherapy for humans |
| 04/21/2009 | CA2400317C Improved paste formulations |
| 04/21/2009 | CA2338358C Compounds and compositions for delivering active agents |
| 04/21/2009 | CA2336902C Topical compositions comprising an opioid analgesic and an nmda antagonist |
| 04/21/2009 | CA2309038C Use of inhaled no as anti-inflammatory agent |
| 04/21/2009 | CA2289122C Bak promoter expression system |
| 04/19/2009 | CA2607149A1 Predicting responsiveness to cancer therapeutics |
| 04/16/2009 | WO2009049230A2 Microsphere-based materials with predefined 3d spatial and temporal control of biomaterials, porosity and/or bioactive signals |
| 04/16/2009 | WO2009049208A1 Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| 04/16/2009 | WO2009048603A1 Methods and kits for the treatment of diverticular conditions |
| 04/16/2009 | WO2009048072A1 ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 |
| 04/16/2009 | WO2009047903A1 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient |
| 04/16/2009 | WO2009047826A2 Pharmaceutical composition comprising sucralphate and mesalazine |
| 04/16/2009 | WO2009047537A1 Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 04/16/2009 | WO2009047291A2 Use of quaternary pyridinium salts for inhibiting cancer metastases |
| 04/16/2009 | WO2009046801A1 Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin |
| 04/16/2009 | WO2009046632A1 Pharmaceutical composition containing angiotensin ii receptor blocker and b family vitamins and use thereof |
| 04/16/2009 | WO2009046631A1 Pharmaceutical composition containing angiotensin converting enzyme inhibitor and b family vitamins and use thereof |
| 04/16/2009 | WO2009046535A1 Methods for assaying mc1r variants and mitochondrial markers in skin samples |
| 04/16/2009 | WO2009002652A3 Use of surfactants for treating mycobacterial infections |
| 04/16/2009 | WO2008115707A3 Post-exposure prophylaxis and treatment of infections caused by anthrax |
| 04/16/2009 | WO2008067027A3 Compositions of chkl inhibitors and cyclodextrin |
| 04/16/2009 | WO2006119083A3 Treating gastrointestinal diseases with modulation of retonic acid |
| 04/16/2009 | WO2006062808A3 Stabilized products, process and devices for preparing same |
| 04/16/2009 | WO2005112567A3 Vaginal microbicide |
| 04/16/2009 | WO2005042727A3 Methods of organ regeneration |
| 04/16/2009 | US20090099254 Method and Kit for Regulation of Microvascular Tone |
| 04/16/2009 | US20090099241 Pharmaceutical composition containing antihypertensive agents |
| 04/16/2009 | US20090099238 Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment |
| 04/16/2009 | US20090099225 Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
| 04/16/2009 | US20090099223 Methods of treating hormone-related conditions using thio-oxindole derivatives |
| 04/16/2009 | US20090099202 External Preparation for Athlete's Foot Treatment |
| 04/16/2009 | US20090099148 Combinations comprising antimuscarinic agents and pde4 inhibitors |
| 04/16/2009 | US20090099139 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 04/16/2009 | US20090099110 Antiviral oligonucleotides |
| 04/16/2009 | US20090099037 Genomic Screen for Epigenetically Silenced Genes Associated With Cancer |
| 04/16/2009 | US20090098569 Novel PGC-1 Isoforms and Uses Therefor |
| 04/16/2009 | US20090098544 Marker molecules associated with lung tumors |
| 04/16/2009 | US20090098197 Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome |
| 04/16/2009 | US20090098177 Methods and devices for tissue repair |
| 04/16/2009 | US20090098157 Helicobacter Pylori Vaccination |
| 04/16/2009 | US20090098120 Compositions and methods for the treatment of immune related diseases |
| 04/16/2009 | US20090098117 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 04/16/2009 | US20090098098 Anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use |
| 04/16/2009 | DE202009000862U1 Dosiereinheit und Zusammensetzung zur Behandlung von entzündlichen Erkrankungen des Mund- und Rachenraums Dosing and composition for the treatment of inflammatory diseases of the mouth and throat |
| 04/16/2009 | CA2704009A1 Preparation, use of preparation for treatment, and method of treatment of intestinal infection |
| 04/16/2009 | CA2702335A1 Microsphere-based materials with predefined 3d spatial and temporal control of biomaterials, porosity and/or bioactive signals |
| 04/16/2009 | CA2702221A1 Methods and kits for the treatment of diverticular conditions |
| 04/16/2009 | CA2702212A1 Methods for assaying mc1r variants and mitochondrial markers in skin samples |
| 04/16/2009 | CA2701880A1 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient |
| 04/16/2009 | CA2701838A1 Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin |
| 04/16/2009 | CA2698326A1 Antibody targeting osteoclast-related protein siglec-15 |
| 04/15/2009 | EP2048157A1 Polynucleotide encoding the rg1 polypeptide |
| 04/15/2009 | EP2047865A1 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 04/15/2009 | EP2047864A1 Use of rpn2 gene expression inhibitor |
| 04/15/2009 | EP2047863A1 Preventive or remedy for inflammatory disease |
| 04/15/2009 | EP2047846A2 Process for stabilizing hydroquinone |
| 04/15/2009 | EP2046812A1 A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide |